Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration

Fernández, Erlinda; Toledo, Jorge R.; Chiong, Maylin; Parra, Francisco; Rodríguez, Elsa; Montero, Carlos; Méndez, Lídice; Capucci, Lorenzo; Farnós, Omar

doi:10.1016/j.vetimm.2011.05.007

Cited by 21 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3E). These results are consistent with previous reports that Ad5-vectored vaccines could provide rapid and sustained protective immunity (11,12,(25)(26)(27)(28).…”

Section: Discussionsupporting

confidence: 93%

An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen

Zhang¹,

Jex²,

Feng³

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

cBacillus anthracis is the causative agent of anthrax, and its spores have been developed into lethal bioweapons. To mitigate an onslaught from airborne anthrax spores that are maliciously disseminated, it is of paramount importance to develop a rapidresponse anthrax vaccine that can be mass administered by nonmedical personnel during a crisis. We report here that intranasal instillation of a nonreplicating adenovirus vector encoding B. anthracis protective antigen could confer rapid and sustained protection against inhalation anthrax in mice in a single-dose regimen in the presence of preexisting adenovirus immunity. The potency of the vaccine was greatly enhanced when codons of the antigen gene were optimized to match the tRNA pool found in human cells. In addition, an adenovirus vector encoding lethal factor can confer partial protection against inhalation anthrax and might be coadministered with a protective antigen-based vaccine.

show abstract

“…3E). These results are consistent with previous reports that Ad5-vectored vaccines could provide rapid and sustained protective immunity (11,12,(25)(26)(27)(28).…”

Section: Discussionsupporting

confidence: 93%

An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen

Zhang¹,

Jex²,

Feng³

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Several heterologous expression systems or recombinant animal viruses have been developed to produce recombinant versions of the VP60 protein. The VP60 recombinant protein has been produced in Escherichia coli [140]; insect cultured cells [59,101-104]; yeast [207,208]; plants [209-213]; insect larvae [214] and recombinant animal-derived viruses [215-219]. Most of these systems were shown to be immunogenic and to confer protection against lethal doses of RHDV by eliciting a humoral response indicating that they are good substitutes for the tissue vaccines.…”

Section: Prevention Control and Vaccinationmentioning

confidence: 99%

Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review

Abrantes

Loo

Pendu

et al. 2012

Vet Res

344

452

View full text Add to dashboard Cite

Rabbit haemorrhagic disease virus (RHDV) is a calicivirus of the genus Lagovirus that causes rabbit haemorrhagic disease (RHD) in adult European rabbits (Oryctolagus cuniculus). First described in China in 1984, the virus rapidly spread worldwide and is nowadays considered as endemic in several countries. In Australia and New Zealand where rabbits are pests, RHDV was purposely introduced for rabbit biocontrol. Factors that may have precipitated RHD emergence remain unclear, but non-pathogenic strains seem to pre-date the appearance of the pathogenic strains suggesting a key role for the comprehension of the virus origins. All pathogenic strains are classified within one single serotype, but two subtypes are recognised, RHDV and RHDVa. RHD causes high mortality in both domestic and wild adult animals, with individuals succumbing between 48-72 h post-infection. No other species has been reported to be fatally susceptible to RHD. The disease is characterised by acute necrotising hepatitis, but haemorrhages may also be found in other organs, in particular the lungs, heart, and kidneys due to disseminated intravascular coagulation. Resistance to the disease might be explained in part by genetically determined absence or weak expression of attachment factors, but humoral immunity is also important. Disease control in rabbitries relies mainly on vaccination and biosecurity measures. Such measures are difficult to be implemented in wild populations. More recent research has indicated that RHDV might be used as a molecular tool for therapeutic applications. Although the study of RHDV and RHD has been hampered by the lack of an appropriate cell culture system for the virus, several aspects of the replication, epizootology, epidemiology and evolution have been disclosed. This review provides a broad coverage and description of the current knowledge on the disease and the virus.

show abstract

“…Currently, commercially available vaccines are produced from tissues collected from experimentally infected rabbits. It has been reported that the capsid protein (VP60) of RHDV has good immunogenicity, and rabbits inoculated with enough recombinant VP60 can be fully protected from wild-type RHDV [8,26]. The capsid protein gene has been subsequently expressed in a number of heterologous hosts to obtain a recombinant vaccine against RHDV [5,8,9,18,25].…”

Section: Discussionmentioning

confidence: 99%

“…However, this strategy raises serious concerns about biological safety, contaminating residues, and animal welfare issues. During the past 20 years, the capsid (VP60) gene was successfully expressed in several heterologous systems [3-5,8,9] and has been shown to confer full protection against lethal challenge with RHDV in rabbits. For example, Fernández et al [8] constructed a single-dose adenovirus vector vaccine against RHDV that induced a potent and long-lasting immune response against RHDV after parenteral or mucosal administration.…”

Section: Introductionmentioning

confidence: 99%

“…During the past 20 years, the capsid (VP60) gene was successfully expressed in several heterologous systems [3-5,8,9] and has been shown to confer full protection against lethal challenge with RHDV in rabbits. For example, Fernández et al [8] constructed a single-dose adenovirus vector vaccine against RHDV that induced a potent and long-lasting immune response against RHDV after parenteral or mucosal administration. An insect larvae-derived recombinant subunit vaccine against RHDV was also developed by Pérez-Filgueira et al [25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Codon optimization of the rabbit hemorrhagic disease virus (RHDV) capsid gene leads to increased gene expression inSpodoptera frugiperda9 (Sf9) cells

Gao

Chen

et al. 2013

J Vet Sci

View full text Add to dashboard Cite

Rabbit hemorrhagic disease (RHD) is contagious and highly lethal. Commercial vaccines against RHD are produced from the livers of experimentally infected rabbits. Although several groups have reported that recombinant subunit vaccines against rabbit hemorrhagic disease virus (RHDV) are promising, application of the vaccines has been restricted due to high production costs or low yield. In the present study, we performed codon optimization of the capsid gene to increase the number of preference codons and eliminate rare codons in Spodoptera frugiperda 9 (Sf9) cells. The capsid gene was then subcloned into the pFastBac plasmid, and the recombinant baculoviruses were identified with a plaque assay. As expected, expression of the optimized capsid protein was markedly increased in the Sf9 cells, and the recombinant capsid proteins self-assembled into virus-like particles (VLPs) that were released into the cell supernatant. Rabbits inoculated with the supernatant and the purified VLPs were protected against RHDV challenge. A rapid, specific antibody response against RHDV was detected by an ELISA in all of the experimental groups. In conclusion, this strategy of producing a recombinant subunit vaccine antigen can be used to develop a low-cost, insect cell-derived recombinant subunit vaccine against RHDV.

show abstract

Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration

Cited by 21 publications

References 49 publications

An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen

An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen

Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review

Codon optimization of the rabbit hemorrhagic disease virus (RHDV) capsid gene leads to increased gene expression inSpodoptera frugiperda9 (Sf9) cells

Contact Info

Product

Resources

About